Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age

Next Previous
Trial Profile

Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DTaP poliovirus vaccine (Primary) ; DTaP vaccine; Measles mumps and rubella virus vaccine; Poliovirus vaccine inactivated; Varicella zoster virus vaccine live
  • Indications Chickenpox; Diphtheria; Measles; Mumps; Pertussis; Poliomyelitis; Rubella; Tetanus; Varicella zoster virus infections
  • Focus Pharmacodynamics

    • Most Recent Events

    • 25 Mar 2015 According to Sanofi Pasteur media release, DTaP-poliovirus-vaccine [Quadracel] has been approved by the US FDA for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age, based on data from this trial.
    • 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Jul 2013 Actual patient number added 3372 according to ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top